focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half

Thu, 26th Oct 2023 18:12

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Wednesday and Thursday, and not separately reported by Alliance News:

----------

Riverstone Credit Opportunities Income PLC - London-based energy infrastructure and energy transition credit investor - Net asset value at September 30 was USD1.07, unchanged from June 30. Says this stability was due to continued strong portfolio performance during the third quarter of 2023, and that as of September 30 it is nearly fully invested based on the revolving credit facility added in the fourth quarter last year and on current portfolio commitments. Riverstone Credit says it remains extremely well positioned due to its portfolio of accredited energy-transition focused investments through green or sustainability-linked structured loans. Notes "backdrop of strong energy market performance, the global focus on decarbonisation and the company's unique focus on short duration lending."

----------

Bloomsbury Publishing PLC - London-based publisher - Pretax profit for the half year ended August 31 was up 8% to GBP14.0 million from GBP12.9 million the year before. Says revenue increased 11% to GBP136.7 million from GBP122.9 million, and diluted earnings per share rose 11% to 13.66 pence from 12.30p. Consumer revenue grew 17% to GBP89.4 million, Adult Trade revenue rose 8% to GBP27.6 million and Children's Trade revenue grew 22% to GBP61.7 million. Declares interim dividend of 3.70p per share, more than double 1.41p the prior year. Cash at August 31 totalled GBP39.1 million, down from GBP41.5 million on the same day in 2022. Says it is confident it will achieve market expectations for the year ending February 29 2024, meaning revenue of GBP273.1 million and profit before tax and "highlighted items" of GBP32.5 million.

----------

Schroder Income Growth Fund PLC - UK-based investment company - Lifts dividend for the year ended August 31 by 4.6% to 13.80p per share from 13.20p the year before. Net asset value total return was positive 4.2%, underperforming against positive 5.2% from the FTSE All Share Total Return index. NAV per share decreased to 293.58p from 295.26p. Says many challenges "look set to continue into the year ahead."

----------

Haydale Graphene Industries PLC - Carmarthenshire, Wales-based technology solutions company - Pretax loss for the year ended June 30 widens to GBP6.6 million compared with GBP5.2 million the previous year. Revenue increased 48% to GBP4.3 million from GBP2.9 million, with US sales continuing to progress on "growth in the core aerospace and automotive markets". Administrative expenses increased 13% to GBP6.3 million from GBP5.5 million. Non-Executive Chair David Banks says: "We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations...the board remains confident that the company will be able to take advantage of the traction it is now seeing."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that in six months ended July 31, pretax loss widened to GBP6.6 million from GBP4.5 million the previous year. Revenue fell 46% to GBP160,000 from GBP295,000. Chief Executive Officer Ali Mortazavi says: "Despite a severe macroeconomic climate, we have made significant progress during the past six months...we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor." Research & development expenditure increased to GBP5.3 million from GBP3.1 million. Company expects higher "underlying cash burn" in the current half year due to its "planned increase in R&D spend to continue the expansion of our AI capabilities and progress the identification and execution of preclinical targets, together with sustaining our active IP strategy as novel inventions are generated."

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
4 Jun 2015 15:22

AGM, EGM Calendar - Week Ahead

Read more
21 May 2015 08:23

e-Therapeutics Says First Patient Enrolled In Phase Ib ETS2101 Trial

Read more
31 Mar 2015 08:21

e-Therapeutics Loss Widens As It Increases Development Spending

Read more
26 Feb 2015 14:12

e-Therapeutics Believes Drug Discovery Process Producing Higher Yield

Read more
23 Jan 2015 13:36

UK DIRECTOR DEALINGS SUMMARY: Shanta Gold Non-Executive Sells Stake

Read more
21 Jan 2015 11:42

DIRECTOR DEALINGS: e-Therapeutics Finance Director Buys 150,000 Shares

Read more
16 Oct 2014 07:40

E-Therapeutics Appoints Sean Nicholson As Executive Director

Read more
16 Sep 2014 09:08

e-Therapeutics Loss Widens On Pipeline Development; Chair To Retire

Read more
9 Jul 2014 07:37

UK MORNING BRIEFING: Deutsche Bank Raises Shell View, Cuts BP

Read more
4 Jul 2014 16:30

Daily Mail General Trust's Chairman sells £15.91m-worth of shares

Viscount Rothermere, the Chairman of Daily Mail and General Trust, has traded in £15.91m-worth of shares in the multi-media and information company. Selling the stock at 860p a piece, Rothermere benefited from the rise seen in the group's share price this week, which has seen it climbed 5.56%, or

Read more
4 Jul 2014 08:59

DIRECTOR DEALINGS: e-Therapeutics Finance Chief Buys 100,000 Shares

Read more
25 Jun 2014 16:02

DIRECTOR DEALINGS: e-Therapeutics Non-Executives Allotted New Shares

Read more
12 May 2014 11:49

e-Therapeutics Loss Widens As It Continues Pipeline Development

LONDON (Alliance News) - e-Therapeutics PLC Monday posted a widened pretax loss for 2013 as it continued to invest and develop its pipeline of products. The pharmaceutical company posted a pretax loss of GBP6.1 million, widened from GBP5.0 million, as it upped its research and development e

Read more
8 May 2014 13:30

UK MIDDAY BRIEFING: Centrica Warns, Barclays Restructures

LONDON (Alliance News) - British gas parent Centrica has issued a profit warning Thursday, blaming the extreme winter weather in the US but mild conditions in the UK, as well as the intense pressure that's been put on energy providers in the UK in recent months by politicians

Read more
8 May 2014 12:23

UK WINNERS & LOSERS: Standard Chartered, Barclays Lead FTSE 100 Risers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Barclays, up 4.9%. Barclays has detailed plans to shrink its investment bank with a new round

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.